The discovery of postnatal vasculogenesis and of the important roles played by Endothelial Progenitor Cells (EPCs) was a landmark in vascular biology that forever has changed the concept of neovascularization. In Metabolic Syndrome (MS) most of EPCs biological functions seem to be impaired and associated with deficient vascular repair, with the maintenance of endothelial dysfunction conditions and the progression of atherosclerosis. The therapeutic control of MS-associated cardiovascular risk factors may restore some of EPCs abrogated functional activities preventing cardiovascular disease development.